What Is Sample Size in CCIT?

Sample size in Container Closure Integrity Testing (CCIT) defines how many units from a batch must be tested to generate a statistically defensible conclusion about that batch's integrity. For parenteral sterile products, it is a core element of the release decision — and getting it wrong in either direction carries real consequences.

What does sample size actually determine?

It determines the probability that a defective batch will be detected before release. A sample that is too small provides false assurance. A well-sized sample, drawn correctly, gives manufacturers and regulators confidence that the batch reflects a process performing within its validated state.

Why isn't sample size just a number?

Because sample size has two dimensions: how many and from where. A statistically large sample drawn only from the middle of a production run — missing startup units, end-of-run units, or entire crimping stations — can be numerically adequate and practically blind at the same time. Both dimensions must be designed deliberately.

Why does this matter more for sterile injectables?

A compromised container closure on a sterile injectable represents a direct patient safety risk: potential microbial ingress, loss of sterility, or degraded drug. This elevates CCI from a quality metric to a patient risk control. Sample size decisions must reflect that stakes level.

Does non-destructive testing change the calculation?

Yes, significantly. When a validated deterministic method such as vacuum decay or high-voltage leak detection (HVLD) is used, testing is non-destructive — every tested unit returns to the saleable batch. This removes product loss as a constraint, making it feasible to sample with the intensity the risk actually warrants, including 100% testing for very small lots.